Second-quarter 2015 net sales of $172.8 million increased 161 percent. This was driven by strong growth in each of Horizon's business units: primary care, orphan and specialty, as well as the addition of new medicines to the primary care and orphan business units.

Primary Care Business Unit: Second-quarter DUEXIS sales of $44.2 million increased 148 percent as compared to the second quarter of 2014, driven by accelerating prescription growth. In the second quarter, VIMOVO sales were $39.8 million and PENNSAID 2% sales were $29.4 million. Total prescriptions accelerated across all three medicines in the primary care business unit driven by their differentiated clinical benefits, strong sales and marketing execution and increased access to Horizon's Prescriptions-Made-Easy™, or PME, program. Total prescriptions for DUEXIS, VIMOVO and PENNSAID 2% increased 68 percent, 52 percent and 142 percent, respectively, as compared to the first quarter of 2015.

Orphan Business Unit: ACTIMMUNE sales were $25.8 million in the quarter, representing a 4 percent sequential increase versus the first quarter of 2015. The commercial organization continues to drive awareness of ACTIMMUNE with both patients and physicians as new patients continue to be steadily added to the therapy each quarter. The Hyperion acquisition was completed on May 7, 2015, and approximately two months of sales were recorded for RAVICTI and BUPHENYL in the second quarter, which were $19.0 million and $3.9 million, respectively.

Specialty Business Unit: RAYOS/LODOTRA sales in the second quarter were $10.7 million, increasing 81 percent versus the second quarter of 2014. In April, a comprehensive effort was initiated to provide more patients access to RAYOS through the PME program, which resulted in total prescription growth versus the first quarter of 2015 of nearly 90 percent.

Second-Quarter 2015 Financial Results Note: For additional detail and reconciliation of these amounts and growth rates to the most directly comparable GAAP financial measures, please refer to the summary table below, as well as the detailed tables at the end of this release.

Q2 2015

Q2 2014

(in millions, except per share amounts)

U.S. GAAP

Adjustments

Non-GAAP

U.S. GAAP

Adjustments

Non-GAAP

Net sales

$

172.8

$

-

$

172.8

$

66.1

$

-

$

66.1

Gross profit

111.0

46.5

157.5

41.3

18.8

60.1

Research and development

8.9

(2.2

)

6.7

3.5

(0.5

)

3.0

Sales and marketing

58.1

(5.9

)

52.2

27.1

(1.0

)

26.1

General and administrative

77.2

(54.9

)

22.3

17.7

(8.7

)

9.0

Total operating expenses

144.2

(63.0

)

81.2

48.3

(10.2

)

38.1

Interest expense, net

19.4

(5.6

)

13.8

4.2

(2.3

)

1.9

Loss on induced debt conversion and debt extinguishment

67.1

(67.1

)

-

-

-

-

Loss on derivative fair value

-

-

-

11.0

(11.0

)

-

Other expense, net

9.1

(9.0

)

0.1

4.3

(4.3

)

-

(Benefit) expense for income taxes

(160.7

)

161.1

0.4

0.9

(0.9

)

-

Net income (loss)

31.8

30.1

61.9

(27.8

)

47.6

19.8

EBITDA (1)

(69.8

)

145.9

76.1

(14.5

)

36.0

21.5

Earnings (loss) per share - basic

$

0.21

$

0.20

$

0.41

$

(0.38

)

$

0.65

$

0.27

Earnings (loss) per share - diluted

$

0.20

$

0.19

$

0.39

$

(0.38

)

$

0.58

$

0.20

(1) EBITDA is a non-GAAP measure.

Under U.S. generally accepted accounting principles (GAAP) in the second quarter of 2015, the gross profit ratio was 64.2 percent. The adjusted gross profit ratio in the second quarter of 2015 was 91.1 percent, compared to 90.9 percent in the second quarter of 2014.

On a GAAP basis in the second quarter of 2015, total operating expenses were 83.5 percent of sales, research & development (R&D) expenses were 5.2 percent of sales, sales & marketing (S&M) expenses were 33.6 percent of sales and general & administration (G&A) expenses were 44.7 percent of sales. Adjusted total operating expenses in the second quarter of 2015 were 47.0 percent of sales, adjusted R&D expenses were 3.9 percent of sales, adjusted S&M expenses were 30.2 percent of sales and adjusted G&A expenses were 12.9 percent of sales. Adjusted total operating expenses in the second quarter of 2014 were 57.6 percent of sales.

On a GAAP basis in the second quarter of 2015, net income was $31.8 million. Adjusted net income in the second quarter of 2015 was $61.9 million, or 35.8 percent of sales, compared to $19.8 million, or 30.0 percent of sales, in the second quarter of 2014.

On an unadjusted basis in the second quarter of 2015, EBITDA was a $69.8 million loss. Adjusted EBITDA in the second quarter of 2015 was $76.1 million, or 44.0 percent of sales, compared to $21.5 million, or 32.5 percent of sales, in the second quarter of 2014.

On a GAAP basis in the second quarter of 2015, diluted earnings per share were $0.20. Adjusted diluted earnings per share in the second quarter of 2015 were $0.39, representing growth of 95.0 percent compared to the second quarter of 2014 diluted earnings per share of $0.20. Weighted average shares outstanding used for calculating earnings per share in the second quarter of 2015 were 150.8 million and 159.8 million for basic and diluted earnings per share, respectively.

Cash Flow Statement and Balance Sheet Highlights

On a GAAP basis in the second quarter of 2015, operating cash flow was $41.6 million. Adjusted operating cash flow in the second quarter of 2015 was $129.6 million, which excludes the payment of accrued excise taxes from the Vidara acquisition, debt extinguishment costs and Hyperion transaction costs.

The Company had cash and cash equivalents of $667.1 million as of June 30, 2015, an increase of $122.9 million from March 31, 2015. The net cash flows related to the Hyperion acquisition were $3.0 million. Please see the description of Hyperion acquisition-related cash flows in the tables at the end of this release.

Total principal amount of debt outstanding was $1.275 billion as of June 30, 2015, compared to total principal amount of debt outstanding of $728 million as of March 31, 2015. The $1.275 billion is comprised of $475 million in 6.625 percent senior notes, $400 million in senior secured term loans, and $400 million of 2.5 percent exchangeable senior notes.

Update on Offer to Acquire Depomed, Inc.

On August 3, 2015, Horizon Pharma issued a news release announcing it submitted a written request to Depomed, Inc. to set a record date to determine shareholders eligible to request a special shareholders meeting. Additionally, Horizon Pharma filed a lawsuit challenging the legality of Depomed's poison pill and certain of the bylaw amendments announced by Depomed's board of directors on July 13, 2015. On July 20, the Company increased its offer to acquire Depomed, Inc. to $33.00 from $29.25 per share in an all-stock transaction.

On July 31, 2015, the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance with claims covering PENNSAID 2%. Also, since April, the company received three additional Notices of Allowance from the USPTO with claims covering PENNSAID 2% and one Notice of Allowance each from the USPTO with claims covering RAVICTI and RAYOS.

On July 27, 2015, Horizon Pharma announced a collaboration with Fox Chase Cancer Center to study ACTIMMUNE (interferon gamma-1b) in combination with PD-1/PD-L1 inhibitors in various forms of cancer.

On July 6, 2015, Horizon Pharma filed patent infringement lawsuits against five companies for filing Abbreviated New Drug Applications for PENNSAID 2%.

On June 5, 2015, the company initiated a Phase 3 trial of ACTIMMUNE for the treatment of Friedreich's ataxia, a degenerative neuromuscular disorder, following the receipt of U.S. Food and Drug Administration Fast Track Designation in April.

On May 8, 2015, the company announced the settlement of PENNSAID 2% patent litigation with Perrigo Company plc and its subsidiary Paddock Laboratories, LLC, collectively (Perrigo).

On May 7, 2015, Horizon Pharma completed the acquisition of Hyperion for $1.1 billion in cash and an enterprise value of $958 million.

Conference CallAt 8 a.m. EDT / 1 p.m. IST today, the Company will host a live conference call and webcast to review its financial and operating results and provide a general business update.

The live webcast and a replay may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com. Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast.

A replay of the conference call will be available approximately two hours after the call and accessible through one of the following telephone numbers, using the passcode below:

About Horizon Pharma plcHorizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets seven medicines through its orphan, primary care and specialty business units. Horizon's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.

Note Regarding Use of Non-GAAP Financial MeasuresEBITDA, or earnings before interest, taxes, depreciation and amortization, and adjusted EBITDA are used and provided by Horizon as non-GAAP financial measures. Horizon provides certain other financial measures such as adjusted net income, adjusted net income per share, adjusted gross profit and gross profit ratio, adjusted operating and other expenses and adjusted cash from operations, each of which include adjustments to GAAP figures.Adjustments to Horizon's GAAP figures as well as EBITDA exclude acquisition transaction related expenses, loss on debt extinguishment, as well as non-cash items such as share-based compensation, depreciation and amortization, royalty accretion, non-cash interest expense, and other non-cash adjustments. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. Horizon believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Horizon's financial performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of the company's historical and expected 2015 financial results and trends. In addition, these non-GAAP financial measures are among the indicators Horizon's management uses for planning and forecasting purposes and measuring the Company's performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Horizon has not provided reconciliation of an expected adjusted EBITDA outlook to an expected net income (loss) outlook because certain items that are a component of net income (loss) cannot be reasonably projected, either due to the significant impact of changes in Horizon's stock price on share-based compensation, the variability associated with acquisition related expenses due to timing and other factors.

Forward-Looking StatementsThis press release contains forward-looking statements, including, but not limited to, statements related to Horizon's expected full-year 2015 net sales and adjusted EBITDA guidance and other statements that are not historical facts. These forward-looking statements are based on Horizon's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks that Horizon's actual full-year 2015 financial and operating results may differ from its expectations; Horizon Pharma's ability to grow sales and revenues from existing products; the availability of coverage and adequate reimbursement and pricing from government and third party payers and risks relating to the success of Horizon's Prescriptions-Made-Easy or PME specialty pharmacy program; competition, including potential generic competition; the ability to protect intellectual property and defend patents; regulatory obligations and oversight; and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Horizon's filings and reports with the U.S. Securities and Exchange Commission ("SEC"). Horizon Pharma undertakes no duty or obligation to update any forward-looking statements contained in this presentation as a result of new information.

Additional Information This press release does not constitute an offer to buy or solicitation of any offer to sell or vote securities. This press release contains certain information related to a solicitation by Horizon Pharma of Depomed's shareholders to call a special shareholders meeting to consider certain matters in connection with a proposal which Horizon Pharma has made for a business combination transaction with Depomed. Subject to future developments, Horizon Pharma and Depomed may file one or more solicitation statements, proxy statements or other documents with the SEC in connection with such special shareholders meeting, and Horizon Pharma (and, if a negotiated transaction is agreed upon, Depomed) may file one or more registration statements, prospectuses, proxy statements or other documents with the SEC in connection with the proposed transaction. This communication is not a substitute for any solicitation statement, proxy statement or other document filed with the SEC in connection with such special shareholders meeting or any registration statement, prospectus, proxy statement or other document Horizon Pharma and/or Depomed may file with the SEC in connection with the proposed transaction. Horizon Pharma has filed a preliminary proxy statement and accompanying WHITE proxy card with the SEC with respect to the solicitation of proxies to call a special meeting of shareholders. INVESTORS AND SECURITY HOLDERS OF HORIZON PHARMA AND DEPOMED ARE URGED TO READ CAREFULLY THE SOLICITATION STATEMENT, (INCLUDING ANY AMENDMENTS AND SUPPLEMENTS), THE ACCOMPANYING WHITE PROXY CARD AND OTHER PROXY STATEMENTS AND DOCUMENTS FILED WITH THE SEC IN CONNECTION WITH THE SPECIAL SHAREHOLDERS MEETING AND ANY REGISTRATION STATEMENTS, PROSPECTUSES, PROXY STATEMENTS AND OTHER DOCUMENTS FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT HORIZON PHARMA, DEPOMED, THE SPECIAL SHAREHOLDERS MEETING AND THE PROPOSED TRANSACTION, AS APPLICABLE. Investors and security holders may obtain free copies of these documents (when they are available) and other related documents filed with the SEC at the SEC's web site at www.sec.gov or by directing a request to Horizon Pharma's Investor Relations department at Horizon Pharma, Inc., Attention: Investor Relations, 520 Lake Cook Road, Suite 520, Deerfield, IL 60015 or to Horizon Pharma's Investor Relations department at 224-383-3400 or by email to investor-relations@horizonpharma.com. Investors and security holders may obtain free copies of the documents filed with the SEC on Horizon Pharma's website at www.horizonpharma.com under the heading "Investors" and then under the heading "SEC Filings."

Certain Information Regarding Participants Horizon Pharma and/or Depomed and their respective directors, executive officers and certain other employees may be deemed participants in a solicitation of proxies in connection with the request to call the special shareholders meeting and in connection with the proposed transaction. You can find information about Horizon Pharma's directors, executive officers and such certain other employees in Horizon Pharma's Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the SEC on February 27, 2015, Horizon Pharma's definitive proxy statement filed with the SEC on May 6, 2015, and in Horizon Pharma's Current Report on Form 8-K/A filed with the SEC on July 27, 2015, and in such solicitation statements, proxy statements or other documents that would be filed with the SEC in connection with the special shareholders meeting and the proposed transaction. You can find information about Depomed's directors, executive officers and its employees who are participants in such solicitation in Depomed's definitive proxy statement filed with the SEC on April 16, 2015, and in such solicitation statements, proxy statements or other documents that would be filed with the SEC in connection with the special shareholders meeting and the proposed transaction. These documents are available free of charge at the SEC's web site at www.sec.gov and, with respect to Horizon Pharma, from Investor Relations at Horizon Pharma as described above. Additional information regarding the interests of such potential participants will be included in one or more registration statements, proxy statements or other documents filed with the SEC if and when they become available.

Horizon Pharma plc

Consolidated Statements of Operations

(in thousands, except share and per share data)

Three Months Ended
June 30,

Six Months Ended
June 30,

2015

2014

2015

2014

REVENUES:

Net sales

$

172,821

$

66,062

$

285,962

$

117,988

Cost of goods sold

61,826

24,810

90,679

32,429

Gross profit

110,995

41,252

195,283

85,559

OPERATING EXPENSES:

Research and development

8,922

3,545

15,103

6,378

Sales and marketing

58,056

27,126

105,119

55,821

General and administrative

77,190

17,681

103,470

28,873

Total operating expenses

144,168

48,352

223,692

91,072

Operating loss

(33,173

)

(7,100

)

(28,409

)

(5,513

)

OTHER EXPENSE, NET:

Interest expense, net

(19,448

)

(4,207

)

(29,480

)

(8,414

)

Foreign exchange loss

(87

)

(284

)

(924

)

(322

)

Loss on derivative fair value

-

(10,965

)

-

(214,995

)

Loss on induced conversion of debt and debt extinguishment

(67,080

)

-

(77,624

)

-

Other, net

(9,078

)

(4,333

)

(10,069

)

(5,000

)

Total other expense, net

(95,693

)

(19,789

)

(118,097

)

(228,731

)

Loss before (benefit) expense for income taxes

(128,866

)

(26,889

)

(146,506

)

(234,244

)

(BENEFIT) EXPENSE FOR INCOME TAXES

(160,680

)

880

(158,767

)

(225

)

NET INCOME (LOSS)

$

31,814

$

(27,769

)

$

12,261

$

(234,019

)

Earnings (loss) per share - basic

$

0.21

$

(0.38

)

$

0.09

$

(3.34

)

Weighted average shares outstanding - basic

150,771,902

73,384,801

138,369,537

70,164,267

Earnings (loss) per share - diluted

$

0.20

$

(0.38

)

$

0.08

$

(3.34

)

Weighted average shares outstanding - diluted

159,797,319

73,384,801

145,031,882

70,164,267

Horizon Pharma plc

Consolidated Balance Sheets

(in thousands, except share data)

As of

June 30,

December 31,

2015

2014

ASSETS

CURRENT ASSETS:

Cash and cash equivalents

$

667,057

$

218,807

Restricted cash

600

738

Accounts receivable, net

182,868

73,915

Inventories, net

20,299

16,865

Prepaid expenses and other current assets

11,620

14,370

Deferred tax assets, net

15,767

1,530

Total current assets

898,211

326,225

Property and equipment, net

9,773

7,241

Developed technology, net

1,692,057

696,963

In-process research and development

66,000

66,000

Other intangible assets, net

7,466

7,870

Goodwill

259,565

-

Deferred tax assets, net, non-current

-

18,761

Other assets

9,615

11,564

TOTAL ASSETS

$

2,942,687

$

1,134,624

LIABILITIES AND SHAREHOLDERS' EQUITY

CURRENT LIABILITIES:

Convertible debt, net

$

-

$

48,334

Long-term debt, current portion

4,000

-

Accounts payable

26,224

21,011

Accrued trade discounts and rebates

136,836

76,115

Accrued expenses

79,246

46,625

Accrued royalties, current portion

42,574

25,325

Deferred revenues, current portion

2,019

1,261

Deferred tax liabilities, net

-

721

Total current liabilities

290,899

219,392

LONG-TERM LIABILITIES:

Exchangeable notes, net

274,305

-

Long-term debt, net

858,593

297,169

Accrued royalties, net of current

128,913

48,887

Deferred revenues, net of current

10,004

8,144

Deferred tax liabilities, net, non-current

121,039

19,570

Other-long term liabilities

4,967

1,258

Total long-term liabilities

1,397,821

375,028

COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS' EQUITY:

Ordinary shares, $0.0001 nominal value per share; 300,000,000 shares authorized; 158,732,528 and 124,425,853 issued at June 30, 2015 and December 31, 2014 respectively, and 158,348,162 and 124,041,487 outstanding at June 30, 2015 and December 31, 2014, respectively.

16

13

Treasury stock, 384,366 ordinary shares at March 31, 2015 and December 31, 2014

Remeasurement of royalties for products acquired through business combinations

14,277

13,033

14,277

13,033

Vidara acquisition costs

759

10,125

2,493

14,174

Hyperion acquisition costs

45,930

-

47,850

-

Loss on derivative revaluation

-

10,965

-

214,995

Loss on induced conversion and debt extinguishment

67,080

-

77,624

-

Share-based compensation

24,665

4,160

31,339

6,087

Royalties for products acquired through business combinations (1)

(6,840

)

(2,347

)

(12,036

)

(5,696

)

Total of Non-GAAP adjustments

$

145,871

$

35,936

$

161,547

$

242,593

Adjusted EBITDA

$

76,050

$

21,479

$

108,513

$

30,230

Non-GAAP Gross Profit:

GAAP net sales

$

172,821

$

66,062

$

285,962

$

117,988

GAAP cost of goods sold

61,826

24,810

90,679

32,429

GAAP gross profit

$

110,995

$

41,252

$

195,283

$

85,559

GAAP gross profit %

64

%

62

%

68

%

73

%

Non-GAAP Gross Profit:

GAAP gross profit

$

110,995

$

41,252

$

195,283

$

85,559

Non-GAAP gross profit adjustments:

Remeasurement of royalties for products acquired through business combinations

14,277

13,033

14,277

13,033

Intangible amortization expense (COGS only)

31,628

5,029

49,105

10,056

Accretion of royalty liabilities

3,977

2,953

7,020

2,953

Amortizaton of inventory step-up adjustment

3,341

-

6,495

-

Depreciation (COGS only)

74

148

203

180

Royalties for products acquired through business combinations (1)

(6,840

)

(2,347

)

(12,036

)

(5,696

)

Total of Non-GAAP adjustments

$

46,458

$

18,816

$

65,065

$

20,526

Non-GAAP gross profit

$

157,453

$

60,068

$

260,347

$

106,085

Non-GAAP gross profit %

91

%

91

%

91

%

90

%

Non-GAAP Cash Provided By Operating Activities:

GAAP cash (used in) provided by operating activities

$

41,584

$

16,761

$

(29,155

)

$

16,004

Cash payments of Vidara acquistion costs

11,272

3,369

13,092

8,464

Cash payments for induced debt conversion

4,776

-

10,472

-

Cash payment for debt extinguishment

45,367

-

45,367

-

Payment of original issue discount on debt extinguishment

3,000

-

3,000

-

Cash payments of Hyperion acquistion costs

23,596

-

23,596

-

Non-GAAP cash provided by operating activities

$

129,595

$

20,130

$

66,372

$

24,468

(1) Royalties for products acquired through business combinations relate to VIMOVO, ACTIMMUNE, RAVICTI and BUPHENYL.

Horizon Pharma plc

Certain Income Statement Line Items - Non-GAAP Adjusted

For the Three Months Ended June 30, 2015

(Unaudited)

Sales

COGS

Research &
Development

Sales &
Marketing

General &
Administrative

Interest
Expense

Loss on Induced
Debt Conversion
& Debt
Extinguishment

Other
(Income) Expense

Income Tax
(Benefit) Expense

Total

Non-GAAP Adjustments (in thousands):

Loss on induced conversion and debt extinguistment(1)

-

-

-

-

-

-

67,080

-

-

67,080

Vidara acquisition costs(2)

-

-

-

-

759

-

-

-

-

759

Hyperion acquisition costs(3)

-

-

-

-

36,930

-

-

9,000

-

45,930

Amortization and accretion:

Intangible amortization expense(4)

-

31,628

-

204

-

-

-

-

-

31,832

Amortization of debt discount and deferred financing costs(5)

-

-

-

-

-

5,622

-

-

-

5,622

Accretion of royalty liability(6)

-

3,977

-

-

-

-

-

-

-

3,977

Amortization of inventory step-up adjustment(7)

-

3,341

-

-

-

-

-

-

-

3,341

Remeasurement of royalties for products acquired through business combinations(8)

-

14,277

-

-

-

-

-

-

-

14,277

Stock-based compensation(9)

-

-

2,212

5,735

16,718

-

-

-

-

24,665

Depreciation expense(10)

-

74

-

-

502

-

-

-

-

576

Royalties for products acquired through business combinations(11)

-

(6,840

)

-

-

-

-

-

-

-

(6,840

)

Income tax adjustments(12)

-

-

-

-

-

-

-

-

(161,135

)

(161,135

)

Total of non-GAAP adjustments

-

46,458

2,212

5,939

54,909

5,622

67,080

9,000

(161,135

)

30,084

Horizon Pharma plc

Certain Income Statement Line Items - Non-GAAP Adjusted

For the Three Months Ended June 30, 2014

(Unaudited)

Sales

COGS

Research &
Development

Sales &
Marketing

General &
Administrative

Interest
Expense

Derivative
Loss

Other
(Income) Expense

Income Tax
(Benefit) Expense

Total

Non-GAAP Adjustments (in thousands):

Loss on derivative revaluation(13)

-

-

-

-

-

-

10,965

-

-

10,965

Vidara acquisition costs(2)

-

-

-

-

5,792

-

-

4,333

-

10,125

Amortization and accretion:

Intangible amortization expense(4)

-

5,029

-

-

-

-

-

-

-

5,029

Amortization of debt discount and deferred financing costs(5)

-

-

-

-

-

2,333

-

-

-

2,333

Accretion of royalty liability(6)

-

2,953

-

-

-

-

-

-

-

2,953

Remeasurement of royalties for products acquired through business combinations(8)

-

13,033

-

-

-

-

-

-

-

13,033

Stock-based compensation(9)

-

-

498

1,040

2,622

-

-

-

-

4,160

Depreciation expense(10)

-

148

-

-

256

-

-

-

-

404

Royalties for products acquired through business combinations(11)

-

(2,347

)

-

-

-

-

-

-

-

(2,347

)

Income tax adjustments(12)

-

-

-

-

-

-

-

-

880

880

Total of non-GAAP adjustments

-

18,816

498

1,040

8,670

2,333

10,965

4,333

880

47,535

Horizon Pharma plc

Certain Income Statement Line Items - Non-GAAP Adjusted

For the Six Months Ended June 30, 2015

(Unaudited)

Sales

COGS

Research &
Development

Sales &
Marketing

General &
Administrative

Interest
Expense

Loss on Induced
Debt Conversion
& Debt
Extinguishment

Other
(Income) Expense

Income Tax
(Benefit) Expense

Total

Non-GAAP Adjustments (in thousands):

Loss on induced conversion and debt extinguistment(1)

-

-

-

-

-

-

77,624

-

-

77,624

Vidara acquisition costs(2)

-

23

94

-

2,376

-

-

-

-

2,493

Hyperion acquisition costs(3)

-

-

-

-

37,850

-

-

10,000

-

47,850

Amortization and accretion:

Intangible amortization expense(4)

-

49,104

-

406

-

-

-

-

-

49,510

Amortization of debt discount and deferred financing costs(5)

-

-

-

-

-

7,848

-

-

-

7,848

Accretion of royalty liability(6)

-

7,020

-

-

-

-

-

-

-

7,020

Amortization of inventory step-up adjustment(7)

-

6,495

-

-

-

-

-

-

-

6,495

Remeasurement of royalties for products acquired through business combinations(8)

-

14,277

-

-

-

-

-

-

-

14,277

Stock-based compensation(9)

-

-

2,670

8,536

20,133

-

-

-

-

31,339

Depreciation expense(10)

-

203

-

-

1,027

-

-

-

-

1,230

Royalties for products acquired through business combinations(11)

-

(12,036

)

-

-

-

-

-

-

-

(12,036

)

Income tax adjustments(12)

-

-

-

-

-

-

-

-

(159,506

)

(159,506

)

Total of non-GAAP adjustments

-

65,087

2,764

8,942

61,386

7,848

77,624

10,000

(159,506

)

74,144

Horizon Pharma plc

Certain Income Statement Line Items - Non-GAAP Adjusted

For the Six Months Ended June 30, 2014

(Unaudited)

Sales

COGS

Research &
Development

Sales &
Marketing

General &
Administrative

Interest
Expense

Derivative
Loss

Other
(Income) Expense

Income Tax
(Benefit) Expense

Total

Non-GAAP Adjustments (in thousands):

Loss on derivative revaluation(13)

-

-

-

-

-

-

214,995

-

-

214,995

Vidara acquisition costs(2)

-

-

-

-

9,174

-

-

5,000

-

14,174

Amortization and accretion:

Intangible amortization expense(4)

-

10,056

-

-

-

-

-

-

-

10,056

Amortization of debt discount and deferred financing costs(5)

-

-

-

-

-

4,666

-

-

-

4,666

Accretion of royalty liability(6)

-

2,953

-

-

-

-

-

-

-

2,953

Remeasurement of royalties for products acquired through business combinations(8)

-

13,033

-

-

-

-

-

-

-

13,033

Stock-based compensation(9)

-

-

798

1,624

3,665

-

-

-

-

6,087

Depreciation expense(10)

-

180

-

-

600

-

-

-

-

780

Royalties for products acquired through business combinations(11)

-

(5,696

)

-

-

-

-

-

-

-

(5,696

)

Income tax adjustments(12)

-

-

-

-

-

-

-

-

(225

)

(225

)

Total of non-GAAP adjustments

-

20,526

798

1,624

13,439

4,666

214,995

5,000

(225

)

260,823

NOTES FOR CERTAIN INCOME STATEMENT LINE ITEMS - NON-GAAP ADJUSTED

(in thousands)

(1)

During the three months ended June 30, 2015, the Company recorded a loss on induced debt conversions of $67,080, which represented an early redemption payment of $45,366, the write-down of $16,733 in debt discount and deferred financing costs, $4,635 in additional exchange consideration to debt holders and $346 in expenses incurred in connection with the induced debt conversions. During the six months ended June 30, 2015, the Company recorded a loss on induced debt conversions of $77,624, which represented an early redemption payment of $45,366, the write-down of $21,581 in debt discount and deferred financing costs, $10,005 in additional exchange consideration to debt holders and $672 in expenses incurred in connection with the induced debt conversions.

(2)

On September 19, 2014, the Company acquired Vidara Therapeutics International Public Limited Company ("Vidara"), through a reverse merger for stock and cash ("Vidara Merger"). Expenses, including legal and consulting fees, incurred in connection with the Vidara Merger, have been excluded as non-recurring items.

(3)

On May 7, 2015, the Company completed its acquisition of Hyperion Therapeutics, Inc. ("Hyperion") pursuant to which the Company acquired all of the issued and outstanding shares of Hyperion's common stock for cash. Expenses, including legal and consulting fees, incurred in connection with the Hyperion acquisition, have been excluded as non-recurring items.

In connection with the Hyperion acquisition, the RAVICTI and BUPHENYL inventory was stepped up in value to $9,125 and during the three months ended June 30, 2015, the Company recognized in cost of goods sold $3,379 of step-up inventory costs related to RAVICTI and BUPHENYL inventory sold. In connection with the Vidara Merger, the ACTIMMUNE inventory was stepped up in value to $14,218 and during the first quarter of 2015, the Company recognized in cost of goods sold the remaining $3,154 of step-up inventory costs related to ACTIMMUNE.

(8)

At the time of the Company's acquisition of the rights to VIMOVO, ACTIMMUNE, RAVICTI and BUPHENYL, the Company estimated the fair value of contingent royalties payable to third parties using an income approach under the discounted cash flow method, which included revenue projections and other assumptions the Company made to determine the fair value. If the Company significantly over performs or underperforms against its original revenue projections or it becomes necessary to make changes to assumptions as a result of a triggering event, the Company is required to reassess the fair value of the contingent royalties payable. Any subsequent adjustments to fair value is recorded in the period such adjustment is made as either an increase or decrease to royalties payable, with a corresponding increase or decrease in cost of goods sold, in accordance with established accounting policies.

During the second quarter of 2015, the Company recorded a charge of $14,277 to cost of goods sold to increase the amount of the contingent royalty liabilities relating to VIMOVO and ACTIMMUNE. During the second quarter of 2014, the Company recorded a charge of $13,033 to cost of goods sold to increase the amount of the contingent royalty liability relating to VIMOVO.

Royalties of $6,840 and $12,036 were incurred during the three and six months ended June 30, 2015, respectively, based on each period's net sales for VIMOVO, ACTIMMUNE, RAVICTI and BUPHENYL, as applicable. Royalties of $2,347 and $5,696 were incurred during the three and six months ended June 30, 2014, respectively, based on each period's net sales for VIMOVO, ACTIMMUNE, RAVICTI and BUPHENYL, as applicable.

(12)

Represents adjustments to convert the income tax expense (benefit) to the estimated amount of taxes that are payable in cash.

(13)

During the three and six months ended June 30, 2014, the Company recorded non-cash charges related to the increase in the fair value of the embedded derivative associated with its convertible senior notes. The loss on the derivative revaluation was primarily due to an increase in the market value of the Company's common stock. The loss on derivative revaluation was a permanent tax difference and was not deductible for income tax reporting purposes.

Horizon Pharma plc

Description of Hyperion acquisition related cash flows

For the three months ended June 30, 2015

(in thousands)

Financing cash flows:

Net proceeds from the issuance of 2023 Senior Notes

$

462,340

Net proceeds from the 2015 Term Loan Facility

391,719

Net proceeds from the issuance of ordinary shares

475,627

Repayment of the 2014 Term Loan Facility

(297,000

)

Net financing cash inflow

1,032,686

Operating cash flows:

Cash payment for debt extinguishment

(45,367

)

Payment of original issue discount upon repayment of 2014 Term Loan Facility